1
|
Shami GJ, Samarska IV, Koek GH, Li A, Palma E, Chokshi S, Wisse E, Braet F. Giant mitochondria in human liver disease. Liver Int 2023; 43:2365-2378. [PMID: 37615254 DOI: 10.1111/liv.15711] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Accepted: 08/11/2023] [Indexed: 08/25/2023]
Abstract
This thematic review aims to provide an overview of the current state of knowledge about the occurrence of giant mitochondria or megamitochondria in liver parenchymal cells. Their presence and accumulation are considered to be a major pathological hallmark of the health and fate of liver parenchymal cells that leads to overall tissue deterioration and eventually results in organ failure. The first description on giant mitochondria dates back to the 1960s, coinciding with the availability of the first generation of electron microscopes in clinical diagnostic laboratories. Detailed accounts on their ultrastructure have mostly been described in patients suffering from alcoholic liver disease, chronic hepatitis, hepatocellular carcinoma and non-alcoholic fatty liver disease. Interestingly, from this extensive literature survey, it became apparent that giant mitochondria or megamitochondria present themselves with or without highly organised crystal-like intramitochondrial inclusions. The origin, formation and potential role of giant mitochondria remain to-date largely unanswered. Likewise, the biochemical composition of the well-organised crystal-like inclusions and their possible impact on mitochondrial function is unclear. Herein, concepts about the possible mechanism of their formation and three-dimensional architecture will be approached. We will furthermore discuss their importance in diagnostics, including future research outlooks and potential therapeutic interventions to cure liver disease where giant mitochondria are implemented.
Collapse
Affiliation(s)
- Gerald J Shami
- School of Medical Sciences (Molecular and Cellular Biomedicine), The University of Sydney, Sydney, New South Wales, Australia
- Australian Centre for Microscopy and Microanalysis, The University of Sydney, Sydney, New South Wales, Australia
| | - Iryna V Samarska
- Pathology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Ger H Koek
- Department of Internal Medicine division of Gastroenterology & Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Amy Li
- Centre for Healthy Futures, Torrens University Australia, Sydney, New South Wales, Australia
- Department of Pharmacy & Biomedical Sciences, La Trobe University, Melbourne, Victoria, Australia
| | - Elena Palma
- The Roger Williams Institute of Hepatology, Foundation for Liver Research, London, UK
- King's College London, Faculty of Life Sciences and Medicine, London, UK
| | - Shilpa Chokshi
- King's College London, Faculty of Life Sciences and Medicine, London, UK
| | - Eddie Wisse
- Division of Nanoscopy, Multimodal Molecular Imaging Institute, University of Maastricht, Maastricht, The Netherlands
| | - Filip Braet
- School of Medical Sciences (Molecular and Cellular Biomedicine), The University of Sydney, Sydney, New South Wales, Australia
- Australian Centre for Microscopy and Microanalysis, The University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|